Tirzepatide reset the weight-loss benchmark in 2022. Three years later the comparative-effectiveness data has caught up, and the answer to "is tirzepatide better than semaglutide for obesity?" is now anchored in head-to-head trial evidence rather than indirect comparisons. The clinical implications are concrete; the prescribing implications are less so.
The two compounds in one paragraph
Both are once-weekly subcutaneous incretin-mimetic peptides. Semaglutide is a GLP-1 receptor mono-agonist (as Wegovy for chronic weight management at the 2.4 mg dose). Tirzepatide is a dual GIP/GLP-1 receptor co-agonist (as Zepbound at doses up to 15 mg). The shared mechanism is incretin pathway activation — slowed gastric emptying, post-prandial insulin support, central appetite suppression. The mechanistic divergence is GIP receptor engagement, which preclinical work suggests amplifies GLP-1 effects on energy balance and glucose handling.
SURMOUNT-5: the head-to-head that ended the indirect-comparison era
The SURMOUNT-5 trial reported in 2025 ([Aronne et al., NEJM — PMID 40353578]) randomized adults with obesity to maximum-tolerated tirzepatide versus maximum-tolerated semaglutide 2.4 mg over 72 weeks. Tirzepatide produced statistically greater weight reduction at every prespecified timepoint. The primary endpoint demonstrated approximately 20% body weight loss on tirzepatide compared with approximately 14% on semaglutide. The trial was powered to detect superiority, not non-inferiority, and the result was unambiguous.
Earlier evidence converged on the same direction
SURMOUNT-1 ([Jastreboff et al., NEJM — PMID 35658024]) had previously established tirzepatide's place-in-therapy at 22.5% body weight reduction at the 15 mg dose over 72 weeks in patients without diabetes. STEP-1 ([Wilding et al., NEJM — PMID 33567185]) had set the semaglutide benchmark at 14.9% body weight reduction over 68 weeks. Indirect comparisons of these endpoints had suggested tirzepatide's edge for several years; SURMOUNT-5 confirmed the gap held in a single randomized population.
What the head-to-head doesn't settle
SURMOUNT-5 is one trial in one population. It does not establish:
- Cardiovascular outcomes superiority. Semaglutide has reported cardiovascular benefit in obesity without diabetes ([Lincoff et al., NEJM SELECT — PMID 37952131]). Tirzepatide's CV outcomes data is still maturing.
- Renal outcomes. Semaglutide's FLOW trial ([Perkovic et al., NEJM — PMID 38785209]) demonstrated kidney-disease progression benefit in type 2 diabetes with chronic kidney disease.
- Side-effect tolerability differentials at matched-effect doses. The trial reported broadly similar gastrointestinal adverse-event profiles, but real-world tolerability remains a clinical judgment call.
- Cost-effectiveness or access. List prices and payer coverage are not equivalent across the two compounds.
Where this leaves the GLP-1 versus dual-agonist conversation
The era of debating "is tirzepatide more effective than semaglutide for body weight" is over. Tirzepatide is more effective at maximum-tolerated dose for weight loss. The remaining clinical conversation is which secondary endpoints matter for the individual patient — cardiovascular protection, renal protection, glycemic effect, tolerability profile, and access constraints — and which compound the comparator-trial evidence supports for that endpoint.
For research investigators, SURMOUNT-5 is the pivotal head-to-head reference for any future obesity-pharmacology trial design. Indirect-comparison meta-analyses on this question are now superseded by direct evidence.
Practical context for this site's readers
The compounds discussed here are prescription medications. They are clinically prescribed in the GLP3 Weight Loss program by independent licensed providers following standard-of-care evaluation. Research-grade peptide reference compounds for laboratory investigation are available separately through the Telos catalog and are not substitutes for prescribed therapy.